## Supplementary



| Primer | Sequence ( $5^{\prime}$ to $3^{\prime}$ ') |
| :--- | :--- |
| PIK3CA $^{\text {Oe }}$ | Forward: GAGGATCCCCGGGTACCGGTCGCCACCATGCCTCCACGACCATCATCAGGTGAAC |
| PIK3CA ${ }^{\text {E545K }}$ | Reverse: TCCTTGTAGTCCATACCGTTCAATGCATGCTGTTTAATTGTGTG |
|  | Revward: GAGGATCCCCGGGTACCGGTCGCCACCATGCCTCCACGACCATCATCAGGTGAAC |
| PIK3CA ${ }^{\text {H1047R }}$ | Forward: GAGGATCCCCGGGTACCGGTCGCCACCATGCCTCCACGACCATCATCAGGTG |
|  | Reverse: TCCTTGTAGTCCATACCGTTCAATGCATGCTGTTTAATTGTGTGGAAGATCCAATCCATTTTTGTTG |



Figure S1 Isolation of single cell populations and $\mathrm{IC}_{50}$ analysis for epirubicin. (A) The procedure for isolating and characterizing transfected cells (e.g., MDA-MB-231, wild-type). The P3 section represents the cells isolated. In this figure, few cells can be seen in the P3 section, since wild-type cells did not carry the GFP protein. (B) Initial isolation of transfected populations of MDA-MB-231 cells. Proportion of cells carrying GFP: $73.8 \%$ for PIK3CA ${ }^{\text {crl }}, 99.3 \%$ for PIK3CA ${ }^{\mathrm{Oe}}, 98.9 \%$ for PIK3CA ${ }^{\mathrm{E} 545 \mathrm{~K}}$, and $0 \%$ for PIK3CA ${ }^{\mathrm{H} 1047 \mathrm{R}}$. (C) Second isolation of PIK3CA ${ }^{\text {crrl }}$ and PIK3CA ${ }^{\text {H1047R }}$ MDA-MB-231 cells for their low proportions in initial isolation. Proportion of cells Vcarrying GFP: 97.2\% for PIK3CA ${ }^{\text {crl }}$ and $96.6 \%$ for PIK3CA ${ }^{\text {H1047R }}$. (D) The drug susceptivity of each cell line was determined by cellular drug resistance assay. Cell viability wase measured under different concentrations of epirubicin, and each $\mathrm{IC}_{50}$ value is listed in Table $S 2$.

Table S2 The $\mathrm{IC}_{50}$ value for epirubicin in each cell group ( $\mu \mathrm{mol} / \mathrm{L}$ )

| Cell lines | PIK3CA $^{\text {Ctr }}$ | PIK3CA $^{\text {Oe }}$ | PIK3CA $^{\text {E545K }}$ | PIK3CA $^{\text {H1047R }}$ |
| :--- | :---: | :---: | :---: | :---: |
| MDA-MB-231 | 1.38 | 2.43 | 4.23 | 1.97 |
| MDA-MB-468 | 0.27 | 0.50 | 0.95 | 1.23 |

Table S3 Information of primary antibodies used in Western blot

| Antibody | Dilution | Catalogue number | Manufacturer |
| :--- | :---: | :---: | :---: |
| PI3 Kinase p110a | $1: 1,000$ | 4249 | CST (Cell Signaling Technology) |
| AKT (pan) | $1: 2,000$ | 2920 | CST |
| p-AKT (Ser473) | $1: 2,000$ | 4060 | CST |
| p-AKT (Thr308) | $1: 1,000$ | 13038 | CST |
| p-mTOR (Ser2448) | $1: 1,000$ | 5536 | CST |
| p-p70 S6 Kinase (Thr389) | $1: 1,000$ | 9206 | CST |
| p-p70 S6 Kinase (Ser 371) | $1: 1,000$ | 9208 | CST |
| p-4E-BP1 (Thr37/46) | $1: 1,000$ | 2855 | CST |
| Xiap | $1: 1,000$ | 14334 | CST |
| Bcl-2 | $1: 1,000$ | 3498 | CST |
| $\beta-a c t i n ~$ | $1: 200$ | 47778 | Santa Cruz |
| mTOR | $1: 200$ | 517464 | Santa Cruz |
| Pten | $1: 200$ | 7974 | Santa Cruz |

Table S4 The sequences of the specific primer for mTOR, Pten, PIK3CA, AKT, EIF4EBP1 and $\beta$-actin in RT-qPCR

| Primer | Sequence (5' to 3') |
| :--- | :--- |
| mTOR | Forward: GCCGCGCGAATATTAAAGGAA |
|  | Reverse: TGGTTTCCTCATTCCGGCTC |
| Pten | Forward: ACCCACCACAGCTAGAACTT |
|  | Reverse: GGGAATAGTTACTCCCTTTTGTC |
| PIK3CA | Forward: TTACCCTCTTCTGCCGGAGG |
|  | Reverse: AAGTGGATGCCCCACAGTTC |
| AKT | Forward: GAAGGACGGGAGCAGGC |
|  | Reverse: CTCACGCGCTCCTCTCAG |
| EIF4EBP1 | Forward: GGAGTGTCGGAACTCACCTG |
|  | Reverse: ACACGATGGCTGGTGCTTTA |
| $\beta$-actin | Forward: CCGTTCCGAAAGTTGCCTTTT |
|  | Reverse: ATCATCCATGGTGAGCTGGC |

